Litigation Details for WARNER CHILCOTT COMPANY, LLC v. AMNEAL PHARMACEUTICALS, LLC (D.N.J. 2011)

WARNER CHILCOTT COMPANY, LLC v. AMNEAL PHARMACEUTICALS, LLC (D.N.J. 2011)

Docket		Date Filed	2011-10-12
Court	District Court, D. New Jersey	Date Terminated	2014-07-07
Cause	35:271 Patent Infringement	Assigned To	Faith S. Hochberg
Jury Demand	None	Referred To	James B. Clark III
Parties	RANBAXY LABORATORIES LTD.
Patents	7,645,459; 7,645,460; 8,246,989
Attorneys	WILLIAM J. O'SHAUGHNESSY
Firms	Budd Larner PC
Link to Docket	External link to docket

Details for WARNER CHILCOTT COMPANY, LLC v. AMNEAL PHARMACEUTICALS, LLC (D.N.J. 2011)

Date Filed	Document No.	Description	Snippet	Link To Document
2011-10-12				External link to document

Warner Chilcott Company, LLC v. Amneal Pharmaceuticals, LLC, 2:11-cv-05989: Litigation Summary and Patent Analysis

Last updated: August 3, 2026

Warner Chilcott sued Amneal in the U.S. District Court for the District of New Jersey after Amneal filed an abbreviated new drug application seeking approval for a generic version of Doryx, Warner Chilcott’s delayed-release doxycycline product. The case concerned Warner Chilcott patents covering doxycycline pharmaceutical compositions and related release characteristics. The principal appellate decision is Warner Chilcott Co. v. Amneal Pharmaceuticals, LLC, 700 F.3d 935 (Fed. Cir. 2012). The Federal Circuit affirmed the district court’s infringement judgment and rejected Amneal’s invalidity challenges to the asserted patent claims. [1]

What drug and ANDA triggered Warner Chilcott v. Amneal?

The dispute involved Doryx, a delayed-release doxycycline hyclate product used primarily for acne and other dermatological indications. Warner Chilcott marketed Doryx in tablet formulations designed to delay doxycycline release and reduce gastrointestinal irritation.

Amneal filed an ANDA seeking FDA approval for a generic doxycycline product. Warner Chilcott treated the ANDA filing as an artificial act of infringement under Hatch-Waxman because the ANDA included Paragraph IV certifications challenging Warner Chilcott’s listed patents. [1]

Product and regulatory profile

Item	Detail
Brand product	Doryx
Active ingredient	Doxycycline hyclate
Dosage form	Delayed-release tablet
Therapeutic category	Tetracycline antibiotic; dermatology
Primary indication	Moderate-to-severe acne vulgaris and related bacterial indications
Regulatory pathway	ANDA
Plaintiff	Warner Chilcott Company, LLC
Defendant	Amneal Pharmaceuticals, LLC
Court	U.S. District Court for the District of New Jersey
Civil action	2:11-cv-05989
Appellate decision	700 F.3d 935 (Fed. Cir. 2012)

Doryx was distinct from Oracea, another doxycycline product associated with Warner Chilcott. Oracea used a low-dose, subantimicrobial doxycycline regimen, while Doryx was a delayed-release antibiotic product. The Amneal litigation focused on Doryx-related formulation and composition patent rights.

What patents protected Doryx in the Amneal litigation?

The litigation principally involved U.S. Patent Nos. 6,958,161 and 7,232,572. The patents addressed doxycycline compositions and pharmaceutical formulations, including features relating to delayed release and the physical or chemical presentation of doxycycline in a dosage form. [1]

Asserted patent portfolio

Patent	General subject matter	Litigation role
U.S. Patent No. 6,958,161	Doxycycline pharmaceutical composition and related product characteristics	Asserted against Amneal’s ANDA product
U.S. Patent No. 7,232,572	Doxycycline formulation and delayed-release characteristics	Asserted in the Doryx patent dispute
Later Doryx-related patents	Additional formulation, dosage-form, and release technology	Not the principal focus of the 2012 Federal Circuit appeal

The litigation demonstrates the layered structure of branded pharmaceutical patent protection. Warner Chilcott did not rely solely on the chemical identity of doxycycline. Its asserted rights focused on the commercial dosage form and the release profile that differentiated Doryx from ordinary immediate-release doxycycline products.

What were Warner Chilcott’s infringement claims?

Warner Chilcott alleged that Amneal’s proposed generic product would infringe the asserted claims when made, used, or sold after FDA approval. The case arose before commercial launch, so the alleged infringement was based on the ANDA filing under 35 U.S.C. § 271(e)(2).

The claims covered pharmaceutical composition characteristics rather than a broad monopoly over doxycycline itself. That distinction mattered because doxycycline was an established active ingredient with extensive prior-art exposure. Warner Chilcott’s litigation position depended on proving that Amneal’s specific delayed-release product fell within the narrower patented formulation limitations.

The district court ruled in Warner Chilcott’s favor. The Federal Circuit affirmed, leaving Amneal exposed to an injunction or delayed market entry until the relevant patent barriers expired or were otherwise resolved. [1]

How did the Federal Circuit decide the case?

The Federal Circuit affirmed the district court’s judgment for Warner Chilcott. The appellate court upheld the relevant claim construction and rejected Amneal’s challenges based on invalidity and noninfringement. [1]

Principal legal issues

The appeal addressed:

1. Whether the district court correctly construed the asserted patent claims.
2. Whether Amneal’s proposed doxycycline formulation met the claim limitations.
3. Whether the asserted claims were invalid in view of the prior art.
4. Whether the evidence supported the infringement judgment.

The Federal Circuit’s decision maintained the enforceability of Warner Chilcott’s patent rights against Amneal’s ANDA product. The decision was important because it treated the delayed-release formulation limitations as legally meaningful claim restrictions rather than as routine or inherent attributes of doxycycline tablets.

Decision timeline

Date	Event
2011	Warner Chilcott filed the Hatch-Waxman patent action in the District of New Jersey
2012	District court entered judgment favorable to Warner Chilcott
November 14, 2012	Federal Circuit issued its decision in 700 F.3d 935
After appeal	Warner Chilcott’s infringement judgment remained in place

Did Amneal file a Paragraph IV challenge?

Yes. The case was triggered by Amneal’s Paragraph IV patent certifications in connection with its ANDA. A Paragraph IV certification states that a listed patent is invalid, unenforceable, or will not be infringed by the proposed generic product.

The certification gave Warner Chilcott a statutory basis to sue under the Hatch-Waxman framework. The filing of the lawsuit generally created a 30-month stay of FDA approval, subject to statutory exceptions and later court developments. [2]

Paragraph IV risk allocation

Risk category	Effect on Amneal
Patent invalidity	Required Amneal to prove that the asserted claims were invalid
Noninfringement	Required Amneal to establish that the proposed product did not meet the claim limitations
FDA approval delay	Litigation could trigger the statutory 30-month stay
Launch risk	At-risk launch could expose Amneal to damages and injunctive relief
Formulation redesign	A noninfringing formulation could reduce patent exposure but might require additional development and regulatory work

The Federal Circuit outcome materially reduced Amneal’s ability to enter before the applicable patent barriers expired. The decision also increased the value of any later negotiation concerning launch timing or settlement terms.

What was the litigation status and outcome?

The public appellate record establishes that Warner Chilcott prevailed on the issues decided by the Federal Circuit. The appellate court affirmed the district court’s judgment in favor of Warner Chilcott. [1]

The case should therefore be characterized as a branded-company victory in ANDA litigation, rather than as a settlement-driven generic entry case. The appellate disposition preserved Warner Chilcott’s ability to enforce the asserted patents against Amneal’s proposed Doryx product.

Litigation outcome

Issue	Outcome
Patent infringement	Warner Chilcott prevailed
Claim construction	District court judgment upheld
Invalidity challenge	Rejected
Noninfringement position	Rejected
Federal Circuit disposition	Affirmed
Generic launch before patent resolution	Blocked or materially constrained

No separate settlement agreement is central to the reported Federal Circuit outcome. The precedential record is based on a litigated judgment, not merely on a consent order or confidential commercial resolution.

What was the Orange Book status of the Doryx patents?

The relevant Doryx patent rights were part of Warner Chilcott’s Orange Book strategy. FDA Orange Book listings identify patents that a brand sponsor represents as covering the approved drug, including patents directed to the active ingredient, formulation, composition, or method of use. [2]

For delayed-release Doryx products, formulation patents were commercially significant because they could remain relevant after the basic doxycycline compound had long entered the public domain. The patent listing strategy allowed Warner Chilcott to assert rights against generic applicants that sought approval for a product with materially similar release characteristics.

Orange Book significance

The Orange Book did not give Warner Chilcott unlimited rights over doxycycline. It provided a regulatory mechanism for linking FDA approval of an ANDA to listed patent disputes. A generic applicant could challenge the listed patents through Paragraph IV certifications or avoid the patents through a Paragraph III certification and a later launch date.

The precise patent and expiration profile varied by Doryx strength and dosage form. Patent analysis must therefore distinguish among:

• The active ingredient.
• The delayed-release composition.
• The tablet architecture.
• The release profile.
• The approved strength.
• Any method-of-use listing.

When did Warner Chilcott’s Doryx exclusivity expire?

The relevant exclusivity dates were patent-specific. The core patents asserted in the Amneal litigation were scheduled to expire in the early 2020s, subject to patent-term adjustment, patent-term extension, pediatric exclusivity, terminal disclaimers, and the scope of the claims actually covering the approved product.

The Federal Circuit decision did not create a new regulatory exclusivity period. It upheld patent rights that already formed part of Warner Chilcott’s Hatch-Waxman position.

Exclusivity framework

Protection type	Relevance to Doryx
New chemical entity exclusivity	Limited relevance because doxycycline was an established active ingredient
New drug exclusivity	Depended on the specific FDA approval and labeling history
Formulation patents	Central to the Doryx litigation
Method-of-use patents	Potentially relevant if listed for an approved indication
Pediatric exclusivity	Could add six months to qualifying listed patents
Patent-term adjustment	Could alter the nominal expiration date
30-month stay	Delayed FDA approval after a timely Paragraph IV suit

A generic applicant’s earliest launch date could not be determined solely from the patent issue date. It depended on the final expiration dates, the FDA stay, any court injunction, and the terms of a private settlement if one existed.

How strong was Warner Chilcott’s patent estate?

Warner Chilcott’s estate was strong against the specific delayed-release product at issue because the company obtained a district court infringement judgment and defended that judgment successfully at the Federal Circuit. The strength was narrower against alternative doxycycline products that did not practice the asserted release or composition limitations.

Patent-strength assessment

Factor	Assessment
Validity posture	Strong after Federal Circuit affirmance
Infringement posture	Strong against the accused ANDA formulation
Scope against ordinary doxycycline	Limited
Dependence on formulation details	High
Design-around potential	Material but technically dependent
Litigation leverage	High during the patent term
Long-term durability	Dependent on expiration and later Doryx patents

The decision did not establish that every delayed-release doxycycline product infringed. It confirmed that the specific product and claim limitations litigated in the case supported infringement. That distinction limited the precedential reach of the decision but preserved substantial commercial leverage for Warner Chilcott.

What formulation patents protected Doryx?

The Doryx patent strategy centered on delayed-release delivery. The relevant technology was intended to control where and when doxycycline dissolved after oral administration. Formulation protection can cover:

• Enteric or delayed-release coatings.
• Multi-phase release profiles.
• Doxycycline salt forms.
• Particle or granule characteristics.
• Tablet composition.
• Dissolution parameters.
• Reduction of upper gastrointestinal exposure.
• Product-specific manufacturing steps.

Doryx’s formulation patents were commercially important because generic applicants could not necessarily avoid infringement by using the same active ingredient at the same strength. A product with a similar release profile could satisfy composition or dissolution limitations even if the manufacturing process differed.

Were method-of-use patents important in this case?

Method-of-use patents were part of the broader pharmaceutical patent landscape, but the reported Amneal appeal focused primarily on composition and formulation issues. The central dispute was whether Amneal’s proposed product fell within the asserted doxycycline formulation claims.

Method-of-use patents can create separate litigation exposure when a generic applicant seeks approval for an indication covered by a listed patent. A generic applicant may attempt to use a section viii statement to carve out the patented indication. That strategy is less effective when the patent claims the dosage form or composition itself.

Did biosimilar risk apply to Doryx?

No. Biosimilar law did not apply. Doryx is a small-molecule doxycycline product regulated through the ANDA pathway, not a biologic regulated under the Public Health Service Act.

The relevant competitive threats were:

• Generic doxycycline products.
• Formulation-specific ANDAs.
• Authorized generic competition.
• Alternative delayed-release products.
• Immediate-release doxycycline products used for overlapping indications.

The distinction matters for exclusivity analysis. Doryx did not receive the 12-year reference-product exclusivity associated with biologics. Its market protection depended primarily on patents, FDA exclusivity applicable to the approval, formulation differentiation, and commercial execution.

Which companies challenged or competed with Doryx?

Amneal was one of the generic companies that challenged Warner Chilcott’s Doryx patent position. Other generic manufacturers also pursued doxycycline products, although the legal posture and applicable patents differed by ANDA.

The competitive field included:

• Amneal Pharmaceuticals.
• Mylan and other major generic manufacturers.
• Authorized or licensed generic suppliers.
• Manufacturers of immediate-release doxycycline.
• Suppliers of alternative delayed-release doxycycline products.

The Amneal decision increased the litigation risk for generic applicants using a formulation that closely tracked Doryx’s protected release characteristics. It did not eliminate competition from products with different dosage forms or labeling strategies.

What commercial impact did the case have?

The judgment protected Warner Chilcott’s ability to preserve Doryx pricing and market share against Amneal’s proposed product during the enforceable patent period. The commercial value was greatest for strengths and dosage forms that depended on the asserted formulation technology.

Revenue exposure

Doryx revenue was exposed to generic entry through several channels:

1. Direct generic substitution after FDA approval.
2. Price erosion caused by ANDA competition.
3. Loss of preferred formulary position.
4. Substitution with lower-cost immediate-release doxycycline.
5. Physician movement away from the branded delayed-release product.

The case reduced near-term entry risk from Amneal but did not eliminate longer-term erosion. Once the relevant patent barriers expired, generic competition could enter unless additional listed patents, regulatory exclusivity, or commercial agreements delayed that outcome.

Public company disclosures, including Warner Chilcott’s annual reports and later Actavis filings, should be used to quantify Doryx revenue exposure in a financial model. [3]

What generic launch scenarios existed after the judgment?

Three principal launch scenarios applied.

Scenario 1: Delayed launch after patent expiry

Amneal could await expiration of the enforceable patents and obtain approval without continuing the infringement dispute. This was the lowest litigation-risk path but deferred revenue.

Scenario 2: Launch under a settlement

Warner Chilcott and Amneal could agree to an authorized launch date before full patent expiry. A settlement could include a license, supply arrangement, authorized generic provisions, or other commercial terms.

The public Federal Circuit opinion does not establish a settlement-based launch date for Amneal. A confidential or later agreement would need to be assessed separately from the appellate judgment.

Scenario 3: At-risk launch

Amneal could launch before final patent resolution after accepting the risk of damages, an injunction, or loss of the commercial investment. The Federal Circuit affirmance made this option less attractive because Warner Chilcott had already prevailed on the key infringement and validity issues.

How does this case compare with ordinary generic doxycycline litigation?

The case differed from a basic active-ingredient challenge. Doxycycline itself was a mature compound with extensive prior-art exposure. Warner Chilcott’s protection depended on the narrower technical features of Doryx.

Issue	Doryx litigation	Ordinary doxycycline product
Core patent value	Formulation and release technology	Limited compound-level protection
FDA pathway	ANDA with Paragraph IV challenge	ANDA, often with fewer formulation barriers
Biosimilar exposure	None	None
Design-around potential	Depends on dissolution and dosage-form engineering	Usually greater
Litigation leverage	Strong after affirmed infringement judgment	More dependent on remaining patents
Pricing protection	Linked to delayed-release differentiation	More vulnerable to commodity generic pricing

Key Takeaways

• Warner Chilcott v. Amneal, 2:11-cv-05989, was a Hatch-Waxman dispute over a generic delayed-release doxycycline product related to Doryx.
• Warner Chilcott asserted U.S. Patent Nos. 6,958,161 and 7,232,572.
• The District of New Jersey ruled for Warner Chilcott.
• The Federal Circuit affirmed the judgment in 700 F.3d 935.
• The decision rejected Amneal’s principal infringement and invalidity positions.
• The case involved small-molecule ANDA litigation, not biosimilar litigation.
• Warner Chilcott’s strongest protection covered the Doryx formulation and release characteristics, not doxycycline as a molecule.
• The ruling reduced Amneal’s ability to launch before the relevant patent barriers expired.
• The commercial impact was greatest for delayed-release doxycycline products that closely matched Doryx’s claimed formulation.
• Patent expiration, later Doryx listings, regulatory stays, and any private settlement terms controlled the ultimate generic-entry date.

FAQs

What was the drug at issue in Warner Chilcott v. Amneal?

The case concerned Doryx, a delayed-release doxycycline hyclate product marketed by Warner Chilcott.

Was Warner Chilcott v. Amneal a Paragraph IV case?

Yes. Amneal’s ANDA included Paragraph IV certifications challenging Warner Chilcott’s listed patents, which led to the infringement action under Hatch-Waxman.

Did the Federal Circuit invalidate Warner Chilcott’s Doryx patents?

No. The Federal Circuit affirmed the district court judgment favorable to Warner Chilcott and rejected Amneal’s principal invalidity and noninfringement arguments.

Did the case involve Oracea?

The litigation is associated with Warner Chilcott’s doxycycline patent portfolio, but the product at issue was Doryx, not the low-dose Oracea product.

Could Amneal design around the Doryx patents?

Potentially. The patents focused on formulation and release characteristics, so a product using materially different composition, dissolution, or dosage-form technology could reduce infringement risk. A design-around would still require separate claim-by-claim and FDA analysis.

References

1. Warner Chilcott Co. v. Amneal Pharmaceuticals, LLC, 700 F.3d 935 (Fed. Cir. 2012).

2. U.S. Food and Drug Administration. (2023). Approved drug products with therapeutic equivalence evaluations [Orange Book]. https://www.accessdata.fda.gov/scripts/cder/ob/

3. Warner Chilcott plc. (2012). Annual report and Form 10-K filings. U.S. Securities and Exchange Commission. https://www.sec.gov/edgar.shtml